NKTR Financial Facts
Cost of goods sold: 7.03MInterest expense: -5.61M
See Full Income Statement
Accrued clinical trial expenses: 10.95M
Other current assets: 4.01M
See Full Balance Sheet
Nektar Therapeutics (NKTR) Earnings
|
Expand Research on NKTR
| Next EPS Date | N/A | EPS Growth Rate | +1,127.8% *Last Qtr. |
|---|---|---|---|
| Average EPS % Beat Rate | -305.3% | Revenue Growth Rate | -51.1% *Last Qtr. |
| Average % Move 1-Wk after EPS | +5.2% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
11/6/25  |
Q325 | N/A | -$0.19 | N/A | N/A | $9.84M | N/A | N/A | N/A | ||
| 11/6/25 | Q325 | $1.85 | $0.00 | +$1.85 | $11.79M | N/A | N/A |  | | Details | |
| 8/7/25 | Q225 | -$2.78 | -$0.20 | -$2.58 | $11.17M | $9.74M | N/A | | | Details | |
| 5/8/25 | Q125 | -$0.24 | -$0.16 | -$0.08 | $10.5M | $16.31M | N/A | | | Details | |
| 3/12/25 | Q424 | $0.03 | -$0.16 | +$0.19 | $29.2M | $29.81M | N/A | | | Details | |
| 3/6/25 |
Q424 | N/A | -$0.16 | N/A | N/A | $29.81M | N/A | N/A | N/A | ||
| 3/5/25 |
Q424 | N/A | -$0.16 | N/A | N/A | $29.81M | N/A | N/A | N/A | ||
| 3/3/25 |
Q424 | N/A | -$0.16 | N/A | N/A | $29.81M | N/A | N/A | N/A |
